ArticleEpidemiology and infection2007
Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods.
Article in Epidemiology and infection, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis.BMC pulmonary medicine · 2015Pooled it
- A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.Influenza and other respiratory viruses · 2024Trial
- Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.The Journal of infectious diseases · 2022Trial
- Article
- Circulation patterns and molecular epidemiology of human respiratory syncytial virus over five consecutive seasons in Morocco.Influenza and other respiratory viruses · 2023Article
- Estimating the burden of adult hospitalized RSV infection including special populations.Vaccine · 2022Article
- European multicenter evaluation of Xpert® Xpress SARS-CoV-2/Flu/RSV test.Journal of medical virology · 2021Article
- Recommendations for respiratory syncytial virus surveillance at the national level.The European respiratory journal · 2021Article
- Influenza-associated mortality in South Africa, 2009-2013: The importance of choices related to influenza infection proxies.Influenza and other respiratory viruses · 2018Article
- Retrospective Observational Study of Atypical Winter Respiratory Illness Season Using Real-Time Syndromic Surveillance, England, 2014-15.Emerging infectious diseases · 2017Observational
- Model estimates of the burden of outpatient visits attributable to influenza in the United States.BMC infectious diseases · 2016Article
- Is the onset of influenza in the community age-related?Epidemiology and infection · 2016Article
- Increasing the complexity of respiratory syncytial virus infection: Reactive oxygen species, DNA damage, and premature senescence.Virulence · 2016Article
- Superinfection between influenza and RSV alternating patterns in San Luis Potosí State, México.PloS one · 2015Article
- Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status.Influenza and other respiratory viruses · 2014Article
- Medically attended respiratory syncytial virus infections in adults aged ≥ 50 years: clinical characteristics and outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old.PloS one · 2014Article
- A robust parameter estimation method for estimating disease burden of respiratory viruses.PloS one · 2014Article
- The use of a neonatal mouse model to study respiratory syncytial virus infections.Expert review of anti-infective therapy · 2010Review
- Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the burden of illness due to a spectrum of respiratory diagnostic categories among persons presenting in a sentinel general practice network in England and Wales during periods of influenza and of respiratory syncytial virus (RSV) activity. During all periods of viral activity, incidence rates of influenza-like illness, bronchitis and common cold were elevated compared to those in baseline periods. Excess rates per 100,000 of acute bronchitis were greater in children aged <1 year (median difference 2702, 95% CI 929-4867) and in children aged 1-4 years (994, 95% CI 338-1747) during RSV active periods rather than influenza; estimates for the two viruses were similar in other age groups. Excess rates of influenza-like illness in all age groups were clearly associated with influenza virus activity. For common cold the estimates of median excess rates were significantly higher in RSV active periods for the age groups <1 year (3728, 95% CI 632-5867) and 5-14 years (339, 95% CI 59-768); estimates were similar in other age groups for the two viruses. The clinical burden of disease associated with RSV is as great if not greater than influenza in patients of all ages presenting to general practitioners.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.